Nymox Pharmaceutical Corporation

Nymox Pharmaceutical specializes in the research and development of novel drugs and diagnostic products for the aging population.  Nymox’s lead drug candidate is NX-1207, a proprietary treatment for enlarged prostate or benign prostatic hyperplasia (BPH).  NX-1207 is currently in Phase 3 trials in the United States.  Nymox has other new drug products in development in the fields of cancer, infectious disease, neurodegenerative diseases, and other areas.


Bank Name Nymox Pharmaceutical Corporation
Stock Exchange NASDAQ
Symbol NYMX
Sector Healthcare
Industry In Vitro & In Vivo Diagnostic Substances
Country United States
World Region Amarica
Chairman Dr. Paul Averback
CEO Dr. Paul Averback
Website www.nymox.com
Registered Year 1989